TwinStrand

TwinStrand Biosciences is a Seattle-based biotech startup involved in biosciences research, noted for recent leadership changes including...

Facts

HQ
Seattle
Sectors
Biotechnology, Life Sciences, DNA sequencing
Type
Corporation Seattle business license
Registered name
TwinStrand Biosciences Inc Seattle business license
Stage
Seed

TwinStrand Biosciences CEO Jesse Salk Steps Down Amid Layoffs; Chad Brown Named Interim CEO

TwinStrand Biosciences co-founder Jesse Salk has stepped down as CEO but will remain chief scientific officer and board member, with Chad Brown named interim CEO amid reported layoffs cutting nearly 50% of the workforce at the Seattle-based gene sequencing startup. The company, founded seven years ago and backed by a $50 million Series B round in 2021, declined to comment on the layoffs.

A-Alpha Bio raises $20M Series A led by Madrona to expand Seattle lab and scale protein-discovery platform

University of Washington spinout A-Alpha Bio raised $20 million in Series A funding led by Madrona Venture Group to expand downtown Seattle lab space and grow its machine-learning team for its protein-discovery platform. The company combines computational tools and yeast-based experiments to generate large protein-interaction datasets used to predict therapeutic protein candidates for diseases including COVID-19.

Former Tech Leaders Join Biotech: Isilon Founder Sujal Patel, Ex-Microsoft Terry Myerson and Others Lead AI-Driven Life Sciences Startups

Several former software and tech executives are moving into biotech and life sciences startups, bringing AI, machine learning, and tech-style business models to companies that analyze proteins, microbes, and medical records. Their tech backgrounds are reshaping product development and funding approaches at firms such as Nautilus Biotechnology, Truveta, insitro and Viome.

Phase Genomics CEO Ivan Liachko shifts company to R&D focus after pandemic hits revenue; one furlough, no layoffs

Phase Genomics, a five-year-old University of Washington spinoff led by CEO Ivan Liachko, shifted to skeleton lab crews and remote work during the pandemic, cutting revenue and furloughing one employee while focusing R&D inward to adapt and continue innovating. The company is adjusting its genomics technology amid Seattle's biotech disruption and exploring ways to help with COVID-19 research.

People